EP1617872A4 - Procedes et compositions permettant de renforcer une reponse immune - Google Patents

Procedes et compositions permettant de renforcer une reponse immune

Info

Publication number
EP1617872A4
EP1617872A4 EP04775877A EP04775877A EP1617872A4 EP 1617872 A4 EP1617872 A4 EP 1617872A4 EP 04775877 A EP04775877 A EP 04775877A EP 04775877 A EP04775877 A EP 04775877A EP 1617872 A4 EP1617872 A4 EP 1617872A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
immune response
enhancing immune
enhancing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04775877A
Other languages
German (de)
English (en)
Other versions
EP1617872A2 (fr
Inventor
Richard L Miller
Mark A Tomai
Ross M Kedl
Isidro Angelo E Zarraga
Ronnie Ortiz
James D Stoesz
Paul D Wightman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Innovative Properties Co
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/640,904 external-priority patent/US7427629B2/en
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Publication of EP1617872A2 publication Critical patent/EP1617872A2/fr
Publication of EP1617872A4 publication Critical patent/EP1617872A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
EP04775877A 2003-04-10 2004-04-09 Procedes et compositions permettant de renforcer une reponse immune Withdrawn EP1617872A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US46214003P 2003-04-10 2003-04-10
US10/640,904 US7427629B2 (en) 2002-08-15 2003-08-14 Immunostimulatory compositions and methods of stimulating an immune response
US51525603P 2003-10-29 2003-10-29
US53370303P 2003-12-31 2003-12-31
US54554204P 2004-02-18 2004-02-18
US54542404P 2004-02-18 2004-02-18
PCT/US2004/011085 WO2005001022A2 (fr) 2003-04-10 2004-04-09 Procedes et compositions permettant de renforcer une reponse immune

Publications (2)

Publication Number Publication Date
EP1617872A2 EP1617872A2 (fr) 2006-01-25
EP1617872A4 true EP1617872A4 (fr) 2011-09-07

Family

ID=34923557

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04775877A Withdrawn EP1617872A4 (fr) 2003-04-10 2004-04-09 Procedes et compositions permettant de renforcer une reponse immune

Country Status (5)

Country Link
EP (1) EP1617872A4 (fr)
JP (1) JP2007514644A (fr)
AU (1) AU2004252409A1 (fr)
CA (1) CA2521662A1 (fr)
WO (1) WO2005001022A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006007433A1 (de) * 2006-02-17 2007-08-23 Curevac Gmbh Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure
JP2010507361A (ja) 2006-07-31 2010-03-11 キュアバック ゲーエムベーハー 具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸
WO2009030254A1 (fr) 2007-09-04 2009-03-12 Curevac Gmbh Complexes d'arn et de peptides cationiques pour transfection et immunostimulation
SG188104A1 (en) 2008-01-31 2013-03-28 Curevac Gmbh Nucleic acids comprising formula (nuglxmgnnv)a and derivatives thereof as an immunostimulating agents /adjuvants
WO2010037408A1 (fr) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprenant un arnm complexé et un arnm nu pour déclencher ou augmenter une réponse immunostimulante chez un mammifère et utilisations de ladite composition
ES2656813T3 (es) 2008-10-24 2018-02-28 Glaxosmithkline Biologicals Sa Derivados de imidazoquinolina lipidados
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
BR112013002298A2 (pt) 2010-07-30 2016-05-24 Curevac Gmbh complexação de ácidos nucleicos com componentes catiônicos reticulados com dissulfeto para transfecção e estimulação imunológica.
WO2013113326A1 (fr) 2012-01-31 2013-08-08 Curevac Gmbh Composition pharmaceutique comprenant un complexe support polymère - charge et au moins un antigène de protéine ou de peptide
RU2723328C2 (ru) 2013-08-21 2020-06-09 Куревак Аг Вакцина против респираторно-синцитиального вируса (рсв)
EP3065741B1 (fr) 2013-11-05 2021-09-22 3M Innovative Properties Company Formulations d'injection a base d'huile de sesame
US10369216B2 (en) 2014-04-01 2019-08-06 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
WO2017056494A1 (fr) 2015-09-29 2017-04-06 Sumitomo Dainippon Pharma Co., Ltd. Composés conjugués de l'adénine et leur utilisation comme adjuvants de vaccins
JP6769976B2 (ja) 2015-10-07 2020-10-14 大日本住友製薬株式会社 ピリミジン化合物
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
AU2017292934B2 (en) 2016-07-07 2024-04-04 Bolt Biotherapeutics, Inc. Antibody adjuvant conjugates
BR112021001188A8 (pt) 2018-07-23 2022-12-06 Japan As Represented By The Director General Of Nat Institute Of Infectious Diseases Composição que contém vacina contra a influenza
WO2020190725A1 (fr) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugués ciblant le her2

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0386757A2 (fr) * 1989-03-09 1990-09-12 The Johns Hopkins University School Of Medicine Esters de polyphospho biodégradables
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
WO1997013499A1 (fr) * 1995-10-11 1997-04-17 The University Of British Columbia Formulations de liposomes a base de mitoxantrone
WO2000040228A2 (fr) * 1999-01-08 2000-07-13 3M Innovative Properties Company Formulations et procedes utilises pour le traitement des etats pathologiques des muqueuses au moyen d'un modificateur de la reponse immunitaire
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
WO2002046749A2 (fr) * 2000-12-08 2002-06-13 3M Innovative Properties Company Procede de criblage permettant d'identifier des composes qui induisent de maniere selective la production d'interferon alpha
CN1377648A (zh) * 2002-04-23 2002-11-06 四川大学 皮肤局部用咪喹莫特或其衍生物脂质体及其制备方法和用途
WO2004032829A2 (fr) * 2002-08-15 2004-04-22 3M Innovative Properties Company Compositions immunostimulantes et procedes de stimulation d'une reponse immune
WO2004060967A1 (fr) * 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Procedes de formation d'hydrogels au moyen de compositions de thiosulfonate et leurs utilisations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991017724A1 (fr) * 1990-05-17 1991-11-28 Harbor Medical Devices, Inc. Polymere utilise dans un dispositif medical
US6486214B1 (en) * 1997-09-10 2002-11-26 Rutgers, The State University Of New Jersey Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
US6518280B2 (en) * 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
US6486168B1 (en) * 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0386757A2 (fr) * 1989-03-09 1990-09-12 The Johns Hopkins University School Of Medicine Esters de polyphospho biodégradables
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
WO1997013499A1 (fr) * 1995-10-11 1997-04-17 The University Of British Columbia Formulations de liposomes a base de mitoxantrone
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
WO2000040228A2 (fr) * 1999-01-08 2000-07-13 3M Innovative Properties Company Formulations et procedes utilises pour le traitement des etats pathologiques des muqueuses au moyen d'un modificateur de la reponse immunitaire
WO2002046749A2 (fr) * 2000-12-08 2002-06-13 3M Innovative Properties Company Procede de criblage permettant d'identifier des composes qui induisent de maniere selective la production d'interferon alpha
CN1377648A (zh) * 2002-04-23 2002-11-06 四川大学 皮肤局部用咪喹莫特或其衍生物脂质体及其制备方法和用途
WO2004032829A2 (fr) * 2002-08-15 2004-04-22 3M Innovative Properties Company Compositions immunostimulantes et procedes de stimulation d'une reponse immune
WO2004060967A1 (fr) * 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Procedes de formation d'hydrogels au moyen de compositions de thiosulfonate et leurs utilisations

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"The Merck Index, An encyclopedia of chemicals, drugs, and biologicals 13th Edition", 1 January 2001, MERCK & CO., INC, XP007914381 *
ALEXIOU C ET AL: "LOCOREGIONAL CANCER TREATMENT WITH MAGNETIC DRUG TARGETING", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER REREARCH, US, vol. 60, no. 23, 1 December 2000 (2000-12-01), pages 6641 - 6648, XP001063184, ISSN: 0008-5472 *
HULAND EDITH ET AL: "In vivo system to detect long-term continuous release of bioactive interleukin-2 by immunopharmacological depot preparations in nude mice with human tumors", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol. 121, no. 5, 1995, pages 285 - 290, XP008140263, ISSN: 0171-5216 *
LAMBERT D M: "Rationale and applications of lipids as prodrug carriers", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 11, no. S2, 1 January 2000 (2000-01-01), pages S15 - S27, XP002245016, ISSN: 0928-0987, DOI: 10.1016/S0928-0987(00)00161-5 *
MUI B ET AL: "Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, WILLIAMS AND WILKINS CO, vol. 298, no. 3, 1 September 2001 (2001-09-01), pages 1185 - 1192, XP002228992, ISSN: 0022-3565 *
PACIOTTI G F ET AL: "Comparison of the toxicity and pharmacokinetics of neat and colloidal good bound TNF", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 40, 1 March 1999 (1999-03-01), pages 585, XP001537146, ISSN: 0197-016X *
WANG HUAN ET AL: "Comparison of Transdermal Diffusion in vitro of Imiquimod in Liposomes and Cream", ZHONGGUO YIYAO GONGYE ZAZHI - CHINESE JOURNAL OF PHARMACEUTICALS, SHANGHAI YIYAO GONGYE YANJIUYUAN, SHANGHAI, CN, vol. 34, no. 2, 1 February 2003 (2003-02-01), pages 73 - 75, XP008156372, ISSN: 1001-8255 *
WANG HUAN ET AL: "Preparation Technology of Imiquimod Chitosan Nanoparticle Optimized by Orthogonal Test", ZHONGGUO YAOSHI - CHINA PHARMACIST, YAOWU LIUXINGBINGXUE ZAZHISHE, HUBEI, CN, vol. 5, no. 7, 1 July 2002 (2002-07-01), pages 432 - 433, XP008156371, ISSN: 1008-049X *

Also Published As

Publication number Publication date
EP1617872A2 (fr) 2006-01-25
WO2005001022A2 (fr) 2005-01-06
AU2004252409A1 (en) 2005-01-06
WO2005001022A3 (fr) 2005-09-15
JP2007514644A (ja) 2007-06-07
CA2521662A1 (fr) 2005-01-06

Similar Documents

Publication Publication Date Title
AP2089A (en) Compositions and methods for combination antiviraltherapy
ZA200706251B (en) Immune response modifier formulations and methods
EP1729768A4 (fr) Formulations modificatrices de reponse immunitaire et procedes correspondants
GB0411940D0 (en) Methods and compositions
EP1701725A4 (fr) Methodes et compositions
AP2280A (en) Compositions and methods for increasing telomeraseactivity.
EP1633718A4 (fr) Compositions et procedes d'inhibition du facteur de croissance transformant beta (tgf-$g(b))
EP1624889A4 (fr) Compositions induisant des reponses immunitaires
EP1664746A4 (fr) Capteur d'antioxydants, procedes et compositions associes
EP1545481A4 (fr) Compositions chimiotherapeutiques combinees et procedes correspondant
EP1617872A4 (fr) Procedes et compositions permettant de renforcer une reponse immune
AU2003256805A8 (en) Compounds compositions and methods
EP1773386A4 (fr) Compositions vaccinales et methodes correspondantes
HK1095743A1 (en) Ccn1 compositions and methods ccn1
ZA200600025B (en) Methods and compositions for interferon therapy
EP1483385A4 (fr) Compositions et procedes destines a produire une reponse immunitaire
EP1684771A4 (fr) Composition et procede associe
GB0303609D0 (en) Novel therapeutic method and compositions
EP1711527A4 (fr) Anticorps specifiques de hla-dr, compositions et methodes associees
ZA200508655B (en) Compositions and methods relating to stop-1
AU2003225710A8 (en) Composition and method for enhancing immune response
EP1583557A4 (fr) Compositions vaccinales et procedes
GB0303645D0 (en) Method and compositions for boosting immune response
EP1608970A4 (fr) Compositions de la ccn3 et procedes associes
GB0327050D0 (en) Therapeutic methods compositions and uses

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051110

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20110810

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/48 20060101ALI20110804BHEP

Ipc: A61F 2/76 20060101ALI20110804BHEP

Ipc: A61K 47/00 20060101ALI20110804BHEP

Ipc: A61F 2/06 20060101ALI20110804BHEP

Ipc: A61P 37/00 20060101ALI20110804BHEP

Ipc: A61F 2/24 20060101ALI20110804BHEP

Ipc: A61K 45/00 20060101AFI20110804BHEP

17Q First examination report despatched

Effective date: 20121108

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20190123